公开(公告)号：US20230028114A1

公开(公告)日：2023-01-26

申请号：US17753803

申请日：2020-09-15

Applicant: Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Holger MONENSCHEIN ,  Sean MURPHY ,  Scott OLSEN ,  Natasha O'ROURKE ,  Holly REICHARD ,  Melinda DAVIS ,  Betty LAM

IPC: A61K31/5025 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

公开(公告)号：US11560372B2

公开(公告)日：2023-01-24

申请号：US16606043

申请日：2018-04-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shinobu Sasaki ,  Masaki Seto ,  Kazuaki Takami ,  Haruhi Ando

IPC: C07D405/14 ,  A61P1/10 ,  C07D405/04 ,  C07D409/14

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.

公开(公告)号：US20230000915A1

公开(公告)日：2023-01-05

申请号：US17778611

申请日：2020-11-24

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Shin KANEKO ,  Suguru ARIMA ,  Maiko TAKIGUCHI ,  Yoshiaki KASSAI ,  Akira HAYASHI

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.

公开(公告)号：US20220411752A1

公开(公告)日：2022-12-29

申请号：US17773467

申请日：2020-10-30

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Shin KANEKO ,  Hisashi YANO ,  Tokuyuki SHINOHARA

IPC: C12N5/0783 ,  C12N15/90

Abstract: Provided is an excellent method for producing an IL-4 non-secreting and IFN-γ secreting (Th1-type) or IFN-γ non-secreting and IL-4 secreting (Th2-type) CD4 single-positive T cell (CD4SP T cell). The method for producing the Th1-type or Th2-type CD4SP T cell of the present invention comprises a step of inducing a CD4 single-positive T cell from a hematopoietic stem cell (HSC) and/or a hematopoietic progenitor cell (HPC) substantially defective in a factor involved in IL-4 secretion or a factor involved in IFN-γ secretion.

公开(公告)号：US20220411413A1

公开(公告)日：2022-12-29

申请号：US17872680

申请日：2022-07-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/14 ,  C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D401/06 ,  C07D405/04 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/13 ,  A61K31/325 ,  A61K31/445 ,  A61K31/55 ,  A61K31/045 ,  A61K31/4406

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220409734A1

公开(公告)日：2022-12-29

申请号：US17610391

申请日：2020-05-08

Applicant: Yutaka NISHIMOTO ,  Yumiko ISHII ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Dylan Bradley ENGLAND ,  Steve P. LANGSTON ,  Hong Myung LEE ,  Liting MA ,  Zhan SHI ,  Stepan VYSKOCIL ,  Jianing WANG ,  He XU ,  Yutaka NISHIMOTO ,  Yumiko ISHII

IPC: A61K47/68 ,  A61K47/54 ,  A61K47/60 ,  A61P35/00

Abstract: The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. Formula (I):

公开(公告)号：US20220401443A1

公开(公告)日：2022-12-22

申请号：US17866203

申请日：2022-07-15

Applicant: Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

Inventor： Vijaykumar Reddy RAJASEKHAR ,  Brendan Mark JOHNSON ,  David B. MACLEAN ,  Lynn SEELY ,  Paul N. MUDD, JR.

IPC: A61K31/501 ,  A61P35/00 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

公开(公告)号：US11524957B2

公开(公告)日：2022-12-13

申请号：US17044366

申请日：2019-04-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Lei Zhu ,  John Daniel Bailey ,  Landon Durak ,  Joshua David Waetzig ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Hiroshi Yamaguchi ,  Koichiro Fukuoka ,  Kazuyuki Akiyama

IPC: C07D453/02 ,  C07D409/04

Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 {3H)-one or a salt, hydrate, or tautomer thereof, or any combination thereof, which are Cdc7 kinase inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with Cdc7 activity.

公开(公告)号：US20220331303A1

公开(公告)日：2022-10-20

申请号：US17642337

申请日：2020-09-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Deborah HARTMAN ,  Rebecca EVANS ,  Helene FAESSEL ,  Robert RUBENS ,  Shinichiro TANAKA

IPC: A61K31/445 ,  A61P25/26 ,  A61K45/06

Abstract: Described herein are methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)-piperidine-1-carboxylate (Compound (I)), compositions comprising Compound (I), and the use of Compound (I) for the treatment of excessive sleepiness in a subject in need thereof.

公开(公告)号：US20220323443A1

公开(公告)日：2022-10-13

申请号：US17627857

申请日：2020-07-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Jie Yu ,  Kurt Eng ,  Michael Joseph Kuranda ,  Kazuho Nishimura ,  Cong Li

IPC: A61K31/519 ,  A61K31/555 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and a second therapy.